These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 20966328

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.
    Rubello D, Mazzarotto R, Casara D.
    Eur J Nucl Med; 2000 Apr; 27(4):431-40. PubMed ID: 10805117
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
    Lind P, Gallowitsch HJ.
    Acta Med Austriaca; 1996 Apr; 23(1-2):69-75. PubMed ID: 8767519
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Routine 201Tl scintigraphy in the follow-up of patients with differentiated thyroid carcinoma: diagnostic accuracy and clinical impact.
    Hsu CC, Chen YW, Huang YF, Chuang YW.
    Nucl Med Commun; 2007 Sep; 28(9):681-7. PubMed ID: 17667746
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
    Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H.
    Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. High Level of Agreement Between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases.
    Ruhlmann M, Jentzen W, Ruhlmann V, Pettinato C, Rossi G, Binse I, Bockisch A, Rosenbaum-Krumme S.
    J Nucl Med; 2016 Sep; 57(9):1339-42. PubMed ID: 27151981
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. 99mTc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma.
    Ng DC, Sundram FX, Sin AE.
    J Nucl Med; 2000 Apr; 41(4):631-5. PubMed ID: 10768563
    [Abstract] [Full Text] [Related]

  • 20. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer.
    Sakurai Y, Kawai H, Iwano S, Ito S, Ogawa H, Naganawa S.
    J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.